摘要
幽门螺杆菌是一种定植于胃黏液层和胃黏膜表面的常见致病菌,全球感染率已超过50%。幽门螺杆菌感染与消化性溃疡、慢性胃炎、胃癌等多种消化系统疾病的发生发展有着密切的联系,临床以抗生素为主的联合疗法为常见。随着抗生素的酸不稳定及细菌耐药性的不断升高,幽门螺杆菌的根除率不断下降,为药物递送提出了新的挑战。纳米给药系统在提高药物生物利用度、达到靶向、缓控释递药等方面具有独特优势,为幽门螺杆菌感染治疗带来了机遇。本文分析了H.pylori的结构特征与其定植、耐药性的产生之间的联系,并针对H.pylori特征结构,归纳总结了纳米给药系统在幽门螺杆菌靶向治疗中的研究进展,以期为幽门螺杆菌的治疗研究和制剂开发提供参考。
Helicobacter pylori is a common pathogenic bacterium colonized in the gastric mucosal layer as well as at the gastric epithelial surface,with the global infection rate exceeded 50%.Helicobacter pylori infection is closely related to the occurrence and development of peptic ulcer,chronic gastritis,gastric cancer and other digestive system diseases.Antibiotic-based combination therapy is commonly used in clinical treatment.However,the eradication rate is gradually decreased due to the acid instability of antibiotics and the increasing drug resistance of bacteria,which brings new challenges for the drug delivery.Nanoparticle delivery system has the unique superiorities in improving bioavailability and targeted,sustained and controlled drug delivery,which bring an opportunity to the eradication of Helicobacter pylori.In this paper,the relationship between the structural characteristics of Helicobacter pylori and its colonization and resistance was analyzed.And according to the characteristic structure of Helicobacter pylori,the research progress of nanoparticle delivery system in the targeted therapy of Helicobacter pylori was summarized,so as to provide reference for the treatment research and preparation development of Helicobacter pylori.
作者
严晓敏
王文俊
陈自强
胡慧玲
王战国
Yan Xiao-min;Wang Wen-jun;Chen Zi-qiang;Hu Hui-ling;Wang Zhan-guo(Key Laboratory of Standardization of Chinese Herbal Medicine,Pharmacy College,Chengdu University of Traditional Chinese Medicine,Ministry of Education,State Key Laboratory of Characteristic Chinese Medicine Resources in Southwest China,Chengdu 611137;Collaborative Innovation Laboratory of Metabonomics,College of Medicine,Chengdu University,Standard Research and Extension Base(Collaborative Innovation Center)of Qiang Medicine,Chengdu 610106)
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2022年第11期1149-1155,共7页
Chinese Journal of Antibiotics
基金
成都中医药大学“杏林学者”项目(No.ZRYY1916)。
关键词
幽门螺杆菌
纳米给药系统
抗生素
靶向治疗
Helicobacter pylori
Nanoparticle delivery system
Antibiotic
Targeted therapy
